Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
Farah BalloutHeng LuNadeem BhatLei ChenDunfa PengZheng ChenXi Steven ChenXiaodian SunSilvia GiordanoSimona CorsoAlexander I ZaikaOliver G McDonaldAlan S LivingstoneWael El-RifaiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.